An Improved Robotic Electrophysiology Platform for Arrhythmia Ablation - Arrhythmias are due to irregular contractions and disorganized electrical signals within the heart and are a
leading cause of death in the United States (US). Ventricular tachycardia and ventricular fibrillation are the
most-serious arrhythmias and are associated with 300k annual US deaths. In comparison, atrial fibrillation (AF)
impacts 6M Americans, making it the most common arrhythmia. With nearly 750k annual US hospitalizations
and 130k annual US deaths, AF is associated with the highest medical costs, which are projected to exceed
$50B by 2035. First-line AF therapies rely on pharmaceuticals to prevent blood clots and to restore proper
rhythm. When these approaches fail, catheter ablation is an option. For this procedure, electrical currents (or
coolants) are directed to the catheter’s tip to ablate those tissues disrupting normal electrical signals. Catheter
ablation is an effective and increasingly-used therapy, with more than 500M procedures performed between
2000 and 2013. However, standard methods are complex and expose electrophysiologists to x-rays. Because
manually-deflectable catheters rely on complex tension-wire designs that are operated from a meter away,
errors accumulate in the transmission of forces and torques. As a result, precise catheter navigation and heart-
wall contact are challenging, which can result in injury and AF recurrence (observed in ~50% of those treated).
Robotic platforms attempt to address manual ablation catheter deficiencies. Standard robotic systems
manipulate traditional manual catheters and place the electrophysiologist outside the x-ray field. However, the
technology’s learning curve is high, catheter tip control is unimproved, and systems are expensive. Magnet-
based robotic systems improve upon standard robotic systems by using magnetic fields to apply forces and
torques directly to magnet-tipped catheters, which simplifies the catheters. The result is a technology that
provides improved navigation and better heart-wall contact. However, magnet-based systems are impractically
large, very expensive, hard to install, and difficult to use, in addition to requiring a new c-arm and magnetic
shielding for the room. For these reasons, broad adoption of all AF robotic solutions has been slow.
As opposed to expending energy in fighting the catheter’s restoring force, the proposed technology
redesigns the catheter so that better catheter navigation and heart-wall contact are accomplished using a
system whose magnetic field and mass are 6X and 40X smaller, respectively, than previously possible. The
result is an affordable technology that 1) provides better catheter-tip control and heart-wall contact, 2) offers an
open catheter lumen for electrical leads and irrigation, and 3) does not require custom c-arms and room
construction. The team reflects commercially-successful magnetics, robotics, and electrophysiology experts.
The Phase I effort focuses on proof of concept of the platform. The aims include 1) building the prototype
magnet system, 2) building catheters and advancer, and 3) evaluating the system’s performance in beating
heart phantoms. An FDA pre-submission meeting will be conducted in advance of the Phase II proposal.